Transgene has entered into a collaborative agreement with the International AIDS Vaccine Initiative (IAVI) to manufacture pre-clinical lots of IAVI's constructs for a novel form of vaccine.
These constructs, developed at the National Institute of Allergy and Infectious Disease, National Institutes of Health USA, consist of Modified Vaccinia Ankara (MVA) vectors carrying genes of the Simian Immunodeficiency Virus, or SIV, which, in monkeys, is the equivalent of HIV, which causes AIDS in humans. Transgene will manufacture the lots to be used by IAVI in its pre-clinical studies. Under the agreement, Transgene is entitled to receive payment of an undisclosed amount from IAVI.
"We are pleased to collaborate with such a renowned institution as IAVI on a worldwide public health problem. This agreement is an opportunity for Transgene to leverage its expertise in the production and manufacturing of recombinant vaccines and vectors," said Jean-Francois Carmier, Chief Executive Officer of Transgene.